- Moderna’s candidate vaccine may not be ready for widespread distribution until next spring
- The company CEO said they could get an approval by the early second quarter of 2021
- Trump has repeatedly claimed a vaccine will be available to the general population in weeks
Biotech company and coronavirus vaccine frontrunner Moderna announced Tuesday that its vaccine candidate would not be ready for widespread distribution until next spring.
In an interview with the Financial Times, Moderna CEO Stephane Bancel said the company is unlikely to seek emergency authorization from the U.S. Food and Drug Administration for frontline workers and at-risk individuals until Nov. 25, at the earliest.
Bancel also spoke at a health conference on Wednesday, saying the drugmaker would not seek approval for use in the general population until late January 2021. If the vaccine is proven to be safe and effective, its approval could take until early